SAN DIEGO–(BUSINESS WIRE)–AntiCancer Inc. publicizes that its patent utility on oral methioninase has been allowed by the USA Patent and Trademark Workplace (USPTO). Oral methioninase in preclinical research has proven efficacy in opposition to most cancers of every kind, and in opposition to diabetes, weight problems and fatty liver. Additionally it is predicted to have efficacy in opposition to Covid-19. All of those ailments require the amino acid methionine in abnormally excessive quantities. Oral methioninase acts in opposition to these ailments by proscribing methionine within the physique.
“Methioninase is secure since it may be taken orally,” stated Dr. Qinghong Han, head of oral methioninase growth at AntiCancer and an inventor on the brand new patent. “Oral methioninase acts by drastically proscribing methionine within the digestive system. It has large business potential, as it’s lively in opposition to ailments comparable to most cancers, diabetes, and Covid-19, which all require an elevated quantity of methionine. Simply as thrilling, oral methioninase additionally has the potential to inhibit growing old.”
AntiCancer has spun out a wholly-owned subsidiary Methuselah Prescribed drugs LLC to commercialize methioninase. “The brand new patent will allow AntiCancer and Methuselah to uniquely market methioninase,” stated Dr. Han.
AntiCancer Inc. uniquely additionally gives patient-derived orthotopic xenograft (PDOX) mouse fashions, which most intently resemble the most cancers affected person. AntiCancer additionally gives HDRA three-dimensional tumor tradition for most cancers drug discovery and analysis. Anticancer can be creating tumor- focusing on micro organism; pluripotent hair follicle stem cells which kind neurons and different cell sorts for regenerative drugs and has pioneered tumor-specific fluorescence-guided surgical procedure.
AntiCancer Inc. relies in San Diego and has subsidiaries in Tokyo, Beijing, Seoul and Nanjing. Observe AntiCancer on anticancer.com.